SE8206055L - Med gamma-cyklodextrin bildade inneslutningskomplex av steroidforeningar, forfarande for framstellning derav och lekemedelspreparat innehallande dessainneslutningskomplex - Google Patents

Med gamma-cyklodextrin bildade inneslutningskomplex av steroidforeningar, forfarande for framstellning derav och lekemedelspreparat innehallande dessainneslutningskomplex

Info

Publication number: SE8206055L
Authority: SE; Sweden
Prior art keywords: inclusion complex; cyclodextrin; pictured; gamma; preparing
Prior art date: 1981-10-27

Application number

SE8206055A

Other languages

English (en)

Swedish (sv)

Other versions

SE8206055D0 (sv

Inventor

A Stadler

J Szejtli

I Habon

G Hortobagyi

I Kolbe

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-10-27

Filing date

1982-10-25

Publication date

1983-04-28

1982-10-25 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

1982-10-25 Publication of SE8206055D0 publication Critical patent/SE8206055D0/xx

1983-04-28 Publication of SE8206055L publication Critical patent/SE8206055L/xx

Links

229920000858 Cyclodextrin Polymers 0.000 title abstract 2
150000003431 steroids Chemical class 0.000 title abstract 2
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 title 1
229940080345 gamma-cyclodextrin Drugs 0.000 title 1
239000000126 substance Substances 0.000 title 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
BTTWKVFKBPAFDK-UHFFFAOYSA-N (9beta,10alpha)-Androst-4-ene-3,17-dione Natural products OC1CCC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 BTTWKVFKBPAFDK-UHFFFAOYSA-N 0.000 abstract 1
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 abstract 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 abstract 1
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 abstract 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 1
229940043377 alpha-cyclodextrin Drugs 0.000 abstract 1
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 abstract 1
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 abstract 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
238000000354 decomposition reaction Methods 0.000 abstract 1
229960003957 dexamethasone Drugs 0.000 abstract 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
230000002255 enzymatic effect Effects 0.000 abstract 1
229960003399 estrone Drugs 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
229960001566 methyltestosterone Drugs 0.000 abstract 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 abstract 1
229960004719 nandrolone Drugs 0.000 abstract 1
230000003589 nefrotoxic effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960005205 prednisolone Drugs 0.000 abstract 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
229960002256 spironolactone Drugs 0.000 abstract 1
ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 abstract 1
229960005294 triamcinolone Drugs 0.000 abstract 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/001—Lactones
- C07J21/003—Lactones at position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Nanotechnology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE8206055A 1981-10-27 1982-10-25 Med gamma-cyklodextrin bildade inneslutningskomplex av steroidforeningar, forfarande for framstellning derav och lekemedelspreparat innehallande dessainneslutningskomplex SE8206055L (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU813147A HU190356B (en)	1981-10-27	1981-10-27	Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility

Publications (2)

Publication Number	Publication Date
SE8206055D0 SE8206055D0 (sv)	1982-10-25
SE8206055L true SE8206055L (sv)	1983-04-28

Family

ID=10962794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8206055A SE8206055L (sv)	1981-10-27	1982-10-25	Med gamma-cyklodextrin bildade inneslutningskomplex av steroidforeningar, forfarande for framstellning derav och lekemedelspreparat innehallande dessainneslutningskomplex

Country Status (12)

Country	Link
JP (1)	JPS5883699A (fr)
BE (1)	BE894825A (fr)
DD (1)	DD208549A5 (fr)
DE (1)	DE3238800A1 (fr)
DK (1)	DK474782A (fr)
ES (1)	ES8308571A1 (fr)
FR (1)	FR2515187A1 (fr)
GB (1)	GB2109381A (fr)
HU (1)	HU190356B (fr)
IT (1)	IT1191049B (fr)
NL (1)	NL8204122A (fr)
SE (1)	SE8206055L (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU196230B (en) *	1983-12-29	1988-10-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect
GB2162529B (en) *	1984-06-08	1988-03-02	Nitrokemia Ipartelepek	B-cyclodextrin complex of benzene sulphonyl urea derivatives
US5223295A (en) *	1988-01-22	1993-06-29	Asterol International	Process for the elimination of steroid compounds contained in substance of biological origin
US5229370A (en) *	1988-08-15	1993-07-20	Ammeraal Robert N	Water soluble branched beta cyclodextrin steroid complex
WO1990001320A1 (fr) *	1988-08-15	1990-02-22	American Maize-Products Company	Complexe soluble dans l'eau de cyclodextrine beta ramifiee et de steroide
EP0540751A4 (en) *	1991-05-20	1994-10-26	Eisai Co Ltd	Steroid compound combined with polysaccharide
US20040152664A1 (en) *	1998-09-02	2004-08-05	Allergan, Inc.	Prednisolone compositions
US20040048830A1 (en) *	2000-11-02	2004-03-11	Mingqiang Zhang	Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
EP1216713A1 (fr)	2000-12-20	2002-06-26	Schering Aktiengesellschaft	Compositions de complexes de estrogen-cyclodextrine
EP1216712A1 (fr)	2000-12-20	2002-06-26	Schering Aktiengesellschaft	Complexes d'inclusion de drospirenone et de cyclodextrines
EP1353699B1 (fr) *	2000-12-20	2012-02-01	Bayer Pharma Aktiengesellschaft	Complexes d'inclusion béta-cyclodextrine-drospirenone
US20070020299A1 (en) *	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) *	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20150031532A1 (en) *	2012-03-13	2015-01-29	Amphidex A/S	Production Of Stabilized Channel Type Cyclodextrin Crystals

1981
- 1981-10-27 HU HU813147A patent/HU190356B/hu not_active IP Right Cessation
1982
- 1982-10-20 DE DE19823238800 patent/DE3238800A1/de not_active Withdrawn
- 1982-10-25 SE SE8206055A patent/SE8206055L/xx not_active Application Discontinuation
- 1982-10-26 FR FR8217943A patent/FR2515187A1/fr not_active Withdrawn
- 1982-10-26 NL NL8204122A patent/NL8204122A/nl not_active Application Discontinuation
- 1982-10-26 GB GB08230513A patent/GB2109381A/en not_active Withdrawn
- 1982-10-26 DK DK474782A patent/DK474782A/da not_active Application Discontinuation
- 1982-10-26 IT IT23942/82A patent/IT1191049B/it active
- 1982-10-26 ES ES516840A patent/ES8308571A1/es not_active Expired
- 1982-10-26 DD DD82244272A patent/DD208549A5/de unknown
- 1982-10-27 JP JP57187658A patent/JPS5883699A/ja active Pending
- 1982-10-27 BE BE0/209341A patent/BE894825A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
IT8223942A0 (it)	1982-10-26
SE8206055D0 (sv)	1982-10-25
FR2515187A1 (fr)	1983-04-29
ES516840A0 (es)	1983-09-16
DD208549A5 (de)	1984-04-04
HU190356B (en)	1986-08-28
DK474782A (da)	1983-04-28
GB2109381A (en)	1983-06-02
DE3238800A1 (de)	1983-05-05
NL8204122A (nl)	1983-05-16
ES8308571A1 (es)	1983-09-16
BE894825A (fr)	1983-02-14
JPS5883699A (ja)	1983-05-19
IT1191049B (it)	1988-02-24

Publication	Publication Date	Title
SE8206055L (sv)	1983-04-28	Med gamma-cyklodextrin bildade inneslutningskomplex av steroidforeningar, forfarande for framstellning derav och lekemedelspreparat innehallande dessainneslutningskomplex
DE69333023T2 (de)	2004-05-06	3-beta-hydroxylierte natürliche Steroidderivate enthaltende Arzneimittelzusammensetzungen und ihre Verwendung
AU8090791A (en)	1992-01-07	Aminosteroids for ophthalmic use
NL170420C (nl)	1982-11-01	Werkwijze voor het bereiden van corticoide steroiden en voor een corticoide steroide bevattend preparaat, alsmede gevormd farmaceutisch preparaat.
SE7713341L (sv)	1978-05-27	Sett att framstella grenade och cykloalifatiska estrar ur androstan- och ostranserierna
Hadd et al.	2013	Conjugates of steroid hormones
KR950016715A (ko)	1995-07-20	당의형 약학적 투여 단위
TOWNSLEY	1973	Further studies on the regulation of human placental steroid 3-sulfatase activity
Huhtaniemi et al.	1970	Presence of testosterone and other neutral steroids in human fetal testes
FUKUSHIMA et al.	1963	Steroid production in “nonfunctioning” adrenal cortical tumor
ES476443A1 (es)	1979-10-16	Procedimiento para la preparacion de esterolinas inhibidorasde la sintesis de las prostaglandinas
CA1028952A (fr)	1978-04-04	Methode de preparation de composes d'heteroside de sterols et de steroides
Weintraub et al.	1977	Interaction of steroids with Pseudomonas testosteroni 3-oxosteroid Δ4-Δ5-isomerase
GB1495531A (en)	1977-12-21	11beta-alkyl steroids of the estrane series
YAMAMOTO et al.	1984	Estrogen Biosynthesis in Human Liver A Comparison of Aromatase Activity for C-19 Steroids in Fetal Liver, Adult Liver and Hepatoma Tissues of Human Subjects
GB1328998A (en)	1973-09-05	Process of corticosteroids
CA2096020A1 (fr)	1992-05-31	Steroides a pont 2.beta.,19-methyleneamino, inhibiteurs de l'aromatase
IL51370A0 (en)	1977-04-29	A process for preparing a mixture of androsta-1,4-diene-3,17-dione and androst-4 ene-3,17-dione
JPS51149258A (en)	1976-12-22	A process for preparing steroid derivatives
GB2018257A (en)	1979-10-17	11 beta -Silylation in corticoid synthesis
Berliner et al.	1962	Influence of steroidal structure on glucuronoside formation by mouse liver and kidney.
CA729157A (en)	1966-03-01	Process for preparing androst-4-ene-3,17-dione and androsta-1,4-diene-3,17-dione from steroidal compounds by the action of micro-organisms
AT272536B (de)	1969-07-10	Verfahren zur Herstellung von Androsta-1,4-dien-3,17-dion
GB1244143A (en)	1971-08-25	Trialkyl-silyloxy-steroids
BALESTRERI et al.	1971	Cortisol-binding Capacity of Plasma Transcortin in Subjects treated with various Anabolic Steroids

Legal Events

Date	Code	Title	Description
1995-02-28	NAV	Patent application has lapsed	Ref document number: 8206055-9 Format of ref document f/p: F

Date

Code

Title

Description

1995-02-28

NAV

Patent application has lapsed

Ref document number: 8206055-9

Format of ref document f/p: F